SHOCKWAVE MEDICAL INC (SWAV)
US82489T1043 - Common Stock
We assign a fundamental rating of 6 out of 10 to SWAV. SWAV was compared to 195 industry peers in the Health Care Equipment & Supplies industry. SWAV has an average financial health and profitability rating. SWAV is growing strongly while it is still valued neutral. This is a good combination! These ratings would make SWAV suitable for growth investing!
1. Profitability
1.1 Basic Checks
SWAV had positive earnings in the past year.
In the past year SWAV had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: SWAV reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: SWAV reported negative operating cash flow in multiple years.
1.2 Ratios
SWAV has a Return On Assets of 9.40%. This is amongst the best in the industry. SWAV outperforms 92.31% of its industry peers.
SWAV has a Return On Equity of 22.03%. This is amongst the best in the industry. SWAV outperforms 95.90% of its industry peers.
The Return On Invested Capital of SWAV (9.19%) is better than 89.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.4% | ||
| ROE | 22.03% | ||
| ROIC | 9.19% |
ROA(3y)13.4%
ROA(5y)-1.2%
ROE(3y)20.17%
ROE(5y)0.98%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of SWAV (20.17%) is better than 95.38% of its industry peers.
Looking at the Operating Margin, with a value of 21.78%, SWAV belongs to the top of the industry, outperforming 94.87% of the companies in the same industry.
SWAV has a better Gross Margin (86.93%) than 95.90% of its industry peers.
SWAV's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.78% | ||
| PM (TTM) | 20.17% | ||
| GM | 86.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.99%
GM growth 5Y16.42%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SWAV is destroying value.
Compared to 1 year ago, SWAV has more shares outstanding
The number of shares outstanding for SWAV has been increased compared to 5 years ago.
SWAV has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 9.99 indicates that SWAV is not in any danger for bankruptcy at the moment.
The Altman-Z score of SWAV (9.99) is better than 88.72% of its industry peers.
SWAV has a debt to FCF ratio of 4.42. This is a neutral value as SWAV would need 4.42 years to pay back of all of its debts.
SWAV has a better Debt to FCF ratio (4.42) than 84.62% of its industry peers.
SWAV has a Debt/Equity ratio of 1.09. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of SWAV (1.09) is worse than 77.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.42 | ||
| Altman-Z | 9.99 |
ROIC/WACC0.93
WACC9.87%
2.3 Liquidity
A Current Ratio of 11.76 indicates that SWAV has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 11.76, SWAV belongs to the top of the industry, outperforming 94.36% of the companies in the same industry.
A Quick Ratio of 10.73 indicates that SWAV has no problem at all paying its short term obligations.
SWAV has a better Quick ratio (10.73) than 94.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.76 | ||
| Quick Ratio | 10.73 |
3. Growth
3.1 Past
SWAV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.08%, which is quite impressive.
The Revenue has grown by 49.16% in the past year. This is a very strong growth!
Measured over the past years, SWAV shows a very strong growth in Revenue. The Revenue has been growing by 126.31% on average per year.
EPS 1Y (TTM)22.08%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-1.69%
Revenue 1Y (TTM)49.16%
Revenue growth 3Y120.84%
Revenue growth 5Y126.31%
Revenue growth Q2Q40.96%
3.2 Future
SWAV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.88% yearly.
SWAV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.28% yearly.
EPS Next Y27.87%
EPS Next 2Y27.63%
EPS Next 3Y25.43%
EPS Next 5Y21.88%
Revenue Next Year26.71%
Revenue Next 2Y24.82%
Revenue Next 3Y23.07%
Revenue Next 5Y20.28%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 84.82, the valuation of SWAV can be described as expensive.
SWAV's Price/Earnings ratio is a bit cheaper when compared to the industry. SWAV is cheaper than 69.23% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.20. SWAV is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 66.33, the valuation of SWAV can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SWAV indicates a somewhat cheap valuation: SWAV is cheaper than 72.31% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.60. SWAV is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 84.82 | ||
| Fwd PE | 66.33 |
4.2 Price Multiples
SWAV's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. SWAV is cheaper than 67.69% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SWAV indicates a somewhat cheap valuation: SWAV is cheaper than 74.87% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 74.42 | ||
| EV/EBITDA | 67.3 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SWAV does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of SWAV may justify a higher PE ratio.
A more expensive valuation may be justified as SWAV's earnings are expected to grow with 25.43% in the coming years.
PEG (NY)3.04
PEG (5Y)N/A
EPS Next 2Y27.63%
EPS Next 3Y25.43%
5. Dividend
5.1 Amount
SWAV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SHOCKWAVE MEDICAL INC
NASDAQ:SWAV (4/24/2024, 1:45:56 PM)
328.26
-0.28 (-0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.31B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 84.82 | ||
| Fwd PE | 66.33 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)3.04
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.4% | ||
| ROE | 22.03% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 21.78% | ||
| PM (TTM) | 20.17% | ||
| GM | 86.93% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 11.76 | ||
| Quick Ratio | 10.73 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)22.08%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y27.87%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)49.16%
Revenue growth 3Y120.84%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y